Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables: 2022-2024

Historic Receivables for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Dec 2024 value amounting to $73.1 million.

  • Arcutis Biotherapeutics' Receivables rose 91.48% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.3 million, marking a year-over-year increase of 128.41%. This contributed to the annual value of $73.1 million for FY2024, which is 183.12% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Receivables of $73.1 million as of FY2024, which was up 183.12% from $25.8 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Receivables registered a high of $73.1 million during FY2024, and its lowest value of $8.5 million during FY2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Receivables value was $25.8 million (recorded in 2023), while the average stood at $35.8 million.
  • Data for Arcutis Biotherapeutics' Receivables shows a peak YoY surged of 205.12% (in 2023) over the last 5 years.
  • Arcutis Biotherapeutics' Receivables (Yearly) stood at $8.5 million in 2022, then soared by 205.12% to $25.8 million in 2023, then skyrocketed by 183.12% to $73.1 million in 2024.